• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.05% Nasdaq Down0.18%

    Lexicon Pharmaceuticals, Inc. (LXRX)

    12.26 Up 0.24(2.00%) 4:00PM EDT
    |After Hours : 12.26 0.00 (0.00%) 5:52PM EDT
    ProfileGet Profile for:
    Lexicon Pharmaceuticals, Inc.
    8800 Technology Forest Place
    The Woodlands, TX 77381
    United States - Map
    Phone: 281-863-3000
    Fax: 281-863-8088
    Website: http://www.lexpharma.com

    Index Membership:N/A
    Full Time Employees:106

    Business Summary 

    Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company’s drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that is in Phase III clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound for the treatment of glaucoma. Further, the company’s development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Lexicon Pharmaceuticals, Inc.

    Corporate Governance 
    Lexicon Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Lonnel Coats , 51
    Chief Exec. Officer, Pres and Director
    Mr. Jeffrey L. Wade J.D., 51
    Chief Financial Officer and Exec. VP of Corp. & Admin. Affairs
    Dr. Alan J. Main Ph.D., 62
    Exec. VP of CMC and Supply Operations
    Dr. Pablo Lapuerta M.D., 53
    Chief Medical Officer and Exec. VP
    Dr. Robert J. Lefkowitz M.D., 72
    Consultant, Independent Director and Member of Corp. Governance Committee
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders